MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore MDxHealth’s ability to scale liquid‑biopsy offerings while navigating integration costs, positioning the firm for accelerated growth and profitability in the fast‑growing urology diagnostics market.

Key Takeaways

• Revenue $29.5M, up 19% YoY.
• Liquid test volume +128%, driving growth.
• Operating loss $5.3M, net loss $8.9M widened.
• Earnout payment cut $20M, improving cash flexibility.
• 2026 revenue $137‑140M, EBITDA margin target 10%.

Pulse Analysis

MDxHealth’s Q4 performance illustrates how precision‑diagnostics firms can leverage a balanced test portfolio to sustain top‑line momentum. Revenue growth was anchored by a dramatic rise in liquid‑biopsy volumes, reflecting broader market demand for non‑invasive prostate cancer screening. Despite a modest increase in gross margin to 63.2%, the company absorbed higher operating expenses tied to the ExoDx acquisition, resulting in a widened net loss. Nonetheless, a strong cash position of $29 million provides a buffer as the firm refines its cost structure and scales new offerings.

The integration of ExoDx marks a pivotal shift in MDxHealth’s strategy, converting SelectMDx customers and consolidating the sales force to unlock cross‑selling opportunities. Liquid‑based tests now account for the majority of billable volume, delivering economies of scale that lifted gross profit by 20%. Management emphasized disciplined capital allocation, noting that operating expenses as a percentage of revenue are trending downward even as headcount rises temporarily for integration. The $20 million earnout amendment further enhances financial flexibility, allowing the company to reinvest in R&D and commercial expansion without immediate cash strain.

Looking ahead, MDxHealth projects 2026 revenue between $137 million and $140 million, relying on unit growth rather than price hikes. The firm targets a 10% adjusted EBITDA margin by year‑end, a significant improvement from the current negative position. Clinical collaborations with the University of Oxford, including the GPS PROTECT study, aim to cement the GPS test’s role in NCCN guidelines, strengthening market differentiation. Together, these initiatives position MDxHealth to capture a larger share of the high‑growth urology diagnostics market while advancing profitability and shareholder value.